CASI Pharmaceuticals Inc CASI

NAS: CASI | ISIN: US14757U2087   7/05/2024
2,610 USD (-5,09%)
(-5,09%)   7/05/2024

8 april 2024 · Casi Pharmaceuticals Reports Development Relating To Its Disputes With Juventas · Persbericht

28 maart 2024 · Casi Pharmaceuticals Announces Fourth Quarter And Full-Year 2023 Business And Financial Results · Persbericht

5 maart 2024 · CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China · Persbericht

16 februari 2024 · Casi Pharmaceuticals Announces First Dosing Of Folotyn® In China · Persbericht

8 november 2023 · Casi Pharmaceuticals Announces Market Approval Of Cnct19 By China Nmpa · Persbericht

2 november 2023 · Thinking about buying stock in NXU, AERWINS Technologies, Chevron, CASI Pharmaceuticals, or Aldeyra Therapeutics? · Persbericht

11 augustus 2023 · Casi Pharmaceuticals Announces Second Quarter 2023 Business And Financial Updates · Persbericht

1 augustus 2023 · Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals · Persbericht

20 juli 2023 · CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339 · Persbericht

17 mei 2023 · Casi Pharmaceuticals Announces First Quarter 2023 Financial Results · Persbericht

26 april 2023 · CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022 · Persbericht

26 april 2023 · Casi Pharmaceuticals Announces Fourth Quarter And Full-Year 2022 Financial Results · Persbericht

21 maart 2023 · Casi Pharmaceuticals Completes Redomiciliation Merger · Persbericht

6 januari 2023 · Casi Pharmaceuticals And Cleave Therapeutics Announce Clinical Trial Application Approval For Cb-5339 In Patients With Multiple Myeloma In China · Persbericht

15 december 2022 · Casi Pharmaceuticals' Partner Juventas Announces New Drug Application For Cnct19 Accepted By China National Medical Products Administration · Persbericht

14 november 2022 · Casi Pharmaceuticals Announces Third Quarter 2022 Financial Results · Persbericht

23 september 2022 · Casi Pharmaceuticals Announces Exit Of Juventas Investment To Strengthen Balance Sheet · Persbericht

7 september 2022 · Casi Pharmaceuticals And Bioinvent Announce Dosing Of First Patient In Bi-1206 Phase 1 Clinical Trial For The Treatment Of Relapsed/Refractory Non-Hodgkin's Lymphoma In China · Persbericht

12 augustus 2022 · Casi Pharmaceuticals Announces Second Quarter 2022 Financial Results · Persbericht

5 augustus 2022 · Casi Pharmaceuticals To Report Second Quarter 2022 Financial Results And Host Conference Call August 12, 2022 · Persbericht

Mijn selecties